Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Lynch_syndrome
gptkb:hereditary_nonpolyposis_colorectal_cancer |
| gptkbp:affects |
bile ducts
|
| gptkbp:associated_with |
gptkb:Company
obesity exposure to certain chemicals liver fluke infection |
| gptkbp:caused_by |
inflammation
bile duct obstruction |
| gptkbp:clinical_trial |
ongoing research
lymph node involvement mass in bile duct vascular invasion |
| gptkbp:current_use |
gptkb:cholangiocarcinoma
|
| gptkbp:end_of_life |
5-year survival rate low
|
| gptkbp:genetic_diversity |
gptkb:physicist
SMA D4 mutation |
| gptkbp:geographical_feature |
less common in Western countries
more common in Southeast Asia |
| https://www.w3.org/2000/01/rdf-schema#label |
bile duct cancer
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:number_of_stages |
regional
localized distant |
| gptkbp:occurs_in |
increasing in some regions
|
| gptkbp:population |
more common in older adults
slightly more common in men |
| gptkbp:public_awareness |
public health campaigns ongoing
increased awareness needed |
| gptkbp:research_focus |
biomarkers
new therapies early detection methods |
| gptkbp:risk_factor |
chronic liver disease
primary sclerosing cholangitis |
| gptkbp:screenings |
not routinely screened
|
| gptkbp:social_responsibility |
biopsy
imaging tests poor prognosis |
| gptkbp:supports |
nutritional support
patient support groups palliative care services |
| gptkbp:symptoms |
weight loss
abdominal pain jaundice itching dark urine pale stools |
| gptkbp:treatment |
gptkb:hospital
gptkb:vaccine palliative care radiation therapy chemotherapy targeted therapy depends on stage endoscopic procedures depends on tumor location late diagnosis depends on overall health |